Objective: To evaluate the impact of the digital rectal exam (DRE) on PSA measurements and clinical decision-making.
Methods: Healthy male volunteers between 50 and 70 years old were recruited during a 30-day public screening program. PSA levels were measured using two different methods (standard enhanced chemiluminescence immunoassay-ECLIA, and novel immunochromatography assay-ICA/rapid PSA) in the same blood sample.